Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides glucose for cellular metabolism, replenishing energy stores and correcting hypoglycemia. Sodium chloride and potassium chloride restore electrolyte balance, maintaining osmolality and membrane potentials.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion. Typical adult dose: 1000 mL to 2000 mL per 24 hours, administered at a rate of 50-100 mL/hour, adjusted based on fluid and electrolyte status.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Dextrose: Not applicable (endogenous). Potassium: Rapid distribution phase (1-1.5 h) with terminal half-life 12-24 h (dose-dependent due to intracellular uptake). Sodium and chloride: Governed by renal regulation, no true half-life.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: Dextrose is metabolized to CO2 and water, not excreted unchanged. Sodium and chloride are excreted renally (90-95% of filtered load reabsorbed). Potassium is excreted renally (90% of daily intake, with 10% fecal).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte